盐酸非那吡啶/硫异恶唑(Phenazopyridine Hydrochloride/Sulfisoxazole)

概要

基本信息

药物类型

小分子化药

别名

Azo Gantrisin

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

Roche Holding AG

在研机构-

非在研机构

Roche Holding AG

最高研发阶段撤市

首次获批日期

美国 (1990-08-31)

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C11H12ClN5

InChIKeyQQBPIHBUCMDKFG-UHFFFAOYSA-N

CAS号136-40-3

查看全部结构式(2)

关联

100 项与盐酸非那吡啶/硫异恶唑相关的临床结果

登录后查看更多信息

100 项与盐酸非那吡啶/硫异恶唑相关的转化医学

登录后查看更多信息

100 项与盐酸非那吡啶/硫异恶唑相关的专利（医药）

登录后查看更多信息

6

项与盐酸非那吡啶/硫异恶唑相关的文献（医药）

2019-12-01·Nanoscale Research Letters

Investigation of energy band at atomic layer deposited AZO/β-Ga2O3 ($$ \overline{2}01 $$) heterojunctions

Article

作者: Golosov, Dmitriy Anatolyevich ; Sun, Shun-Ming ; Gu, Chen-Jie ; Ding, Shi-Jin ; Liu, Wen-Jun

The Al-doped effects on the band offsets of ZnO/β-Ga₂O₃ interfaces are characterized by X-ray photoelectron spectroscopy and calculated by first-principle simulations. The conduction band offsets vary from 1.39 to 1.67 eV, the valence band offsets reduce from 0.06 to - 0.42 eV, exhibiting an almost linear dependence with respect to the Al doping ratio varying from 0 to 10%. Consequently, a type-I band alignment forms at the interface of ZnO/β-Ga₂O₃ heterojunction and the AZO/β-Ga₂O₃ interface has a type-II band alignment. This is because incorporating Al into the ZnO would open up the band gaps due to the strong Al and O electron mixing, and the conduction and valence band edges consequently shift toward the lower level.

1970-05-01·The American journal of medical technology

Urine urobilinogen as a component of routine urinalysis.

Article

作者: Free, A H ; Hager, C B

1959-09-01·American journal of obstetrics and gynecology1区 · 医学

Acute urinary tract infection in pregnancy; clinical evaluation of combined sulfisoxazole and phenylazodiamino-pyridine HCl (Azo gantrisin).

1区 · 医学

Article

作者: MULLA, N

100 项与盐酸非那吡啶/硫异恶唑相关的药物交易

登录后查看更多信息